Which progestogen is more likely to increase the risk of fatal myocardial infarction: A combination of epidemiological and trial evidence

Maturitas

Volumn 54, Issue 2, 2006, Pages 154-163

  Al Azzawi, Farook ^a   Thompson, John ^b   Stevenson, John ^c  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

AMORIS; Apolipoprotein AI; Apolipoprotein B; Estrogen; Lipids; Menopause; Progestogens; Trimegestone

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; CHOLESTEROL; ESTRADIOL; GESTAGEN; NORETHISTERONE ACETATE; TRIACYLGLYCEROL; TRIMEGESTONE; TRISEQUENS;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG SAFETY; FEMALE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PROTEIN BLOOD LEVEL; RISK FACTOR; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEINS; CHOLESTEROL; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; PROGESTINS; TRIGLYCERIDES;

EID: 33646143321     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.10.004     Document Type: Article

References (64)

1. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
2. McNagny S.E., Wenger N.K., and Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med 127 (1997) 1093-1096
3. Vestergaard P., Hermann A.P., Gram J., et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 28 (1997) 137-145
4. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
5. Gordon T., Kannel W.B., Hjortland M.C., and McNamara P.M. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 89 (1978) 157-161
6. Stevenson J.C., Crook D., and Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98 (1993) 83-90
7. Gruchow H.W., Anderson A.J., Barboriak J.J., and Sobocinski K.A. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 115 (1988) 954-963
8. Lobo R.A. Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73 (1991) 925-930
9. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., and Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325 (1991) 1196-1204
10. Farish E., Fletcher C.D., Hart D.M., Dagen M.M., and Parkin D.E. Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta 159 (1986) 147-151
11. Gordon D.J., and Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
12. Marsh M.S., Crook D., Whitcroft S.I., Worthington M., Whitehead M.I., and Stevenson J.C. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 83 (1994) 19-23
13. LaRosa J.C. Metabolic effects of estrogens and progestins. Fertil Steril 62 (1994) 140S-146S
14. Kim C.J., Jang H.C., Cho D.H., and Min Y.K. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 14 (1994) 275-281
15. Chen F.P., Lee N., and Soong Y.K. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone. J Reprod Med 43 (1998) 568-574
16. Tremollieres F.A., Pouilles J.M., and Ribot C.A. A prospective 2-year study of progestin given alone in postmenopausal women: effect on lipid and metabolic parameters. Am J Obstet Gynecol 173 (1995) 85-89
17. Steinberg D. The cholesterol controversy is over. Why did it take so long?. Circulation 80 (1989) 1070-1078
18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
19. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
20. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
21. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., and Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 19 (1998) 1434-1503
22. Krauss R.M., Perlman J.A., Ray R., and Petitti D. Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am J Obstetr Gynecol 158 (1988) 1606-1611
23. Schaefer E.J., Lamon-Fava S., Cohn S.D., et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 35 (1994) 779-792
24. Bachorik P.S., Lovejoy K.L., Carroll M.D., and Johnson C.L. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 43 (1997) 2364-2378
25. Connelly P.W., Poapst M., Davignon J., et al. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group. Can J Cardiol 15 (1999) 409-418
26. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 (2001) 481-488
27. Ansell B.J., Navab M., Hama S., et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108 (2003) 2751-2756
28. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004) 529-541
29. Navab M., Hama S.Y., Anantharamaiah G.M., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41 (2000) 1495-1508
30. Navab M., Hama S.Y., Cooke C.J., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41 (2000) 1481-1494
31. Navab M., Anantharamaiah G.M., Hama S., et al. Oral administration of an Apo A-I mimetic Peptide synthesized from d-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105 (2002) 290-292
32. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoproteinmediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109 (2004) 3215-3220
33. Vega G.L., and Grundy S.M. Does measurement of apolipoprotein B have a place in cholesterol management?. Arteriosclerosis 10 (1990) 668-671
34. Sniderman A.D., and Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias. Clin Chem 42 (1996) 489-491
35. Wald N.J., Law M., Watt H.C., et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 343 (1994) 75-79
36. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec cardiovascular study. Circulation 94 (1996) 273-278
37. Rosseneu M., Fruchart J.C., Bard J.M., et al. Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. European Atherosclerosis Research Study. Circulation 89 (1994) 1967-1973
38. Sniderman A.D. Counterpoint: to (measure apo) B or not to (measure apo) B: a critique of modern medical decision-making. Clin Chem 43 (1997) 1310-1314
39. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
40. Marcovina S.M., Albers J.J., Dati F., Ledue T.B., and Ritchie R.F. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 37 (1991) 1676-1682
41. Albers J.J., Marcovina S.M., and Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 38 (1992) 658-662
42. Marcovina S.M., Albers J.J., Henderson L.O., and Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 39 (1993) 773-781
43. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., and Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 40 (1994) 586-592
44. Labeur C., Shepherd J., and Rosseneu M. Immunological assays of apolipoproteins in plasma: methods and instrumentation. Clin Chem 36 (1990) 591-597
45. Stein E. Clinical significance and measurement of apolipoproteins A-1 and B. In: Rifai N., and Warnick G. (Eds). Laboratory measurement of lipids, lipoproteins and apolipoproteins (1994), AACC Press, Washington, DC 141-154
46. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
47. Schaefer E.J., and McNamara J.R. Routine diagnostic testing for apoA-I, apo-B, Lp(a), and LDL cholesterol in clinical laboratories. Clin Lab Sci 7 (1994) 205-208
48. Garfagnini A., Devoto G., Rosselli P., Boggiano P., and Venturini M. Relationship between HDL-cholesterol and apolipoprotein A1 and the severity of coronary artery disease. Eur Heart J 16 (1995) 465-470
49. Westerveld H.T., van Lennep J.E., van Lennep H.W., et al. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol 18 (1998) 1101-1107
50. Francis M.C., and Frohlich J.J. Coronary artery disease in patients at low risk-apolipoprotein AI as an independent risk factor. Atherosclerosis 155 (2001) 165-170
51. Philibert D., Bouchoux F., Degryse M., Lecaque D., Petit F., and Gaillard M. The pharmacological profile of a novel norpregnance progestin (trimegestone). Gynecol Endocrinol 13 (1999) 316-326
52. Al-Azzawi F., Wahab M., Sami S., Proudler A.J., Thompson J., and Stevenson J.C. Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women. Climacteric 7 (2004) 292-300
53. Al-Azzawi F., Wahab M., Thompson J., et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 4 (2001) 343-354
54. Schafer J.L. Analysis of incomplete multivariate data (1997), Chapman and Hall, London
55. Graziani M.S., Zanolla L., Righetti G., Marchetti C., Mocarelli P., and Marcovina S.M. Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group. Clin Chem 44 (1998) 134-140
56. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102 (2000) 1886-1892
57. van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., and van der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 20 (2000) 2408-2413
58. Hara H., and Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem 266 (1991) 3080-3086
59. Marcil M., Brooks-Wilson A., Clee S.M., et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354 (1999) 1341-1346
60. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22 (1999) 352-355
61. Arakawa R., Abe-Dohmae S., Asai M., Ito J.I., and Yokoyama S. Involvement of caveolin-1 in cholesterol enrichment of high density lipoprotein during its assembly by apolipoprotein and THP-1 cells. J Lipid Res 41 (2000) 1952-1962
62. Fielding C.J., Bist A., and Fielding P.E. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci USA 94 (1997) 3753-3758
63. Kojima K., Abe-Dohmae S., Arakawa R., Murakami I., Suzumori K., and Yokoyama S. Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta 1532 (2001) 173-184
64. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712